ANDA Approvals Continue To Accelerate As FDA Breaks Monthly Record
This article was originally published in The Pink Sheet Daily
Agency well positioned for user fee negotiations after third strong month in a row.
You may also be interested in...
US FDA’s Search For Class-Wide Vaccine Blood-Clot Effect Makes Scientific Sense, But Raises Questions
Several adenovirus vaccine developers say the products cannot be compared, potentially complicating the US FDA and CDC’s decision on ending the recommended pause in the use of Janssen’s vaccine.
Based on the historical time between Phase III results and filing announcements, AstraZeneca is way behind the pace. The firm will soon have waited longer to submit its EUA to the US FDA than the three already-authorized products waited combined.
ANDA approval rates have remained steady, while submission rates dropped compared to prior years.